<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/platform.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar/5621345630369022014?origin\x3dhttps://cderwn.blogspot.com', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe" }); } }); </script>

Drug Evaluation & Research

CDERNEW-TEXT 9/17/2007

Tuesday, September 18, 2007

September 17, 2007

Drug Shortage; Drug to be Discontinued; Ethmozine (moricizine
hydrochloride) 200mg, 250g, and 300mg tablets
http://www.fda.gov/cder/drug/shortages/default.htm#Ethmozine (updated)

FDA issues an Alert on the risk of QT prolongation and Torsades de
Pointes (TdP) in patients treated with Haldol (haloperidol). Drug
Information http://www.fda.gov/cder/drug/InfoSheets/HCP/haloperidol.htm

New PDUFA payment procedures for application and supplement fees
effective October 1, 2007
http://www.fda.gov/cder/pdufa/application_fees.htm#new

------------------------------------------------
To subscribe or to unsubscribe from CDERNEW-TEXT

http://list.nih.gov/archives/cdernew-text.html
------------------------------------------------

posted by Mags @ 2:04 PM,

0 Comments: